CrossAssetDataThe Company File
···
IART

Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Princeton, NJ. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.6 billion and a loss of $516 million (its filed statements).

Product business Surgical & Medical Instruments & Apparatus Princeton, NJ filings since 1996 9 of 9 filed
Ask the desk about IART → Compare IART with ICUI → Price chart on TradingView ↗ Full EDGAR file ↗ Watch IART →

Sector peers: ICUIPODDWSTMMED

4.9/10headline grade
vs its business-model standard
6.9/10past 4.4/10present 3.5/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 4.9 out of ten, 9 of 9 metrics filed: past 6.9 out of ten, present 4.4 out of ten, future 3.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.3 out of ten. No warning events in its filings since 2017. 83rd percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.0 out of ten. +5.7% a year over 10 filed years; profitable in 8 of 10. 50th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 8.9 out of ten. Share count shrank 2.8% a year. 100% of cash flow returned. Insiders: 0 sales, 1 purchases. 89th percentile among 40 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 4.7 out of ten. ROE -49%: lost 49¢ per shareholder dollar. Leverage 71%: owes 71¢ per asset dollar. 47th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 5.1 out of ten. top 49% of 109 in its family; net margin -31.6%. 51st percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 2.9 out of ten. bottom 29% of 90 in its family for leadership; chief executive since 2026. 29th percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 3.4 out of ten. bottom 34% of 104 in its family for room to expand. 34th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 4.3 out of ten. bottom 43% of 105 in its family for growth drivers. 43rd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 2.4 out of ten. bottom 24% of 88 in its family for expectations against reality. 24th percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-29 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-10-02 (on EDGAR). Newest filing: Form 8-K, 2026-10-09. Filings on record since 1996. Read from EDGAR 2026-10-12.

Where the revenue comes from

Lines of business in fiscal 2025: Codman Specialty Surgical 73%, Tissue Technologies 27%. By geography: United States 74%, Asia Pacific 12%, Europe 10%, Rest of the World 5%. As tagged in its annual report (Form 10-K, filed 2026-02-26).

Who runs it

Essig, Stuart (President and CEO); Poul, Mojdeh (President & CEO); Davis, Robert T. Jr. (EVP & President, TR&DT); Singh, Harvinder (EVP & President, SS); Knight, Lea Daniels (EVP & Chief Financial Officer); Shinn, Lesha R (CVP, Chief Legal Officer & Sec); Mcbreen, Michael J. (EVP & Chief Commercial Officer); Hutchinson, Michael Damon (EVP, Chief Legal Officer & Sec); Veillon-Berteloot, Chantal (EVP & CHRO); Mosebrook, Jeffrey (SVP, Fin & Princ Acct Officer); and 6 more. 16 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.